Today: 3 April 2026

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals shares fell 3.6% to $67.09 by early afternoon Tuesday, outpacing declines in biotech peers as traders positioned ahead of key January updates. The drop followed recent volatility after FDA approval of REDEMPLO, the company’s first commercial drug for familial chylomicronemia syndrome. Arrowhead plans to release interim obesity-program data and present at the J.P. Morgan Healthcare Conference in early January.
Energy Fuels stock falls today as UUUU pulls back after uranium sales beat, new contracts

Energy Fuels stock falls today as UUUU pulls back after uranium sales beat, new contracts

Energy Fuels Inc shares fell 3.5% to $14.55 in Tuesday afternoon trading, underperforming uranium peers. The company said it exceeded 2025 uranium production guidance and completed two new long-term sales contracts with U.S. nuclear power generators. Energy Fuels expects to sell 360,000 pounds of U3O8 in Q4 for about $27 million at a weighted average price of $74.93 per pound.
30 December 2025
Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

Mineralys Therapeutics shares fell 3.3% to $35.61 by early afternoon Tuesday, underperforming biotech peers as investors awaited updates on its blood-pressure drug lorundrostat. The stock remains up 183% over 52 weeks but is down 25% from its November high. Mineralys plans to file for FDA approval of lorundrostat by early 2026 and expects Phase 2 results in the first quarter of that year.
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals shares dropped 4.2% to $107.85 in early afternoon trading Tuesday as biotech stocks broadly declined. Investors are awaiting an FDA decision on expanding Imcivree’s label, now expected by March 20, 2026. Board member Camille L. Bedrosian resigned effective immediately, according to an SEC filing. Major biotech ETFs fell over 1% while the broader market was flat.
Warby Parker stock price today: WRBY falls nearly 4% in thin year-end trading

Warby Parker stock price today: WRBY falls nearly 4% in thin year-end trading

Warby Parker shares fell 3.9% to $22.11 in early afternoon trading Tuesday, underperforming the broader market amid thin year-end volumes. Nearly 3 million shares changed hands as investors awaited Federal Reserve meeting minutes. The company’s recent AI glasses partnership with Google has drawn attention, but traders remain focused on near-term fundamentals. Retail stocks were mixed, with National Vision down 1.7%.
30 December 2025
France vows stable electricity bills in 2026 — but new charges could still push costs up

France vows stable electricity bills in 2026 — but new charges could still push costs up

France will scrap its ARENH nuclear pricing scheme on Jan. 1, giving EDF more freedom to sell nuclear power. The government says regulated electricity tariffs should remain broadly stable in 2026 and 2027. A new mechanism will claw back excess EDF nuclear revenues above set thresholds, but officials say it is unlikely to trigger soon. Consumer group UFC-Que Choisir warns a separate policy could add about 50 euros to annual household energy bills.
30 December 2025
Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept Therapeutics shares fell 8.9% to $72.72 in early afternoon trading Tuesday as investors awaited the FDA’s decision on relacorilant, due later in the day. SEC filings showed CEO Joseph Belanoff and Chief Business Officer Gary Charles Robb exercised stock options and withheld shares for taxes. About 897,000 shares changed hands. The drop outpaced declines in major biotech indexes.
Equinox Gold stock climbs as gold rebounds — here’s what’s moving EQX today

Equinox Gold stock climbs as gold rebounds — here’s what’s moving EQX today

Equinox Gold shares rose 2.2% to around $14.30 on Tuesday as gold prices rebounded, following a sharp drop the previous day. About 2.2 million shares traded, with the stock moving between $14.18 and $14.58. Investors are watching for Federal Reserve minutes later in the day for signals on 2026 rate cuts. No major company news since Equinox announced its Brazil asset sale on Dec. 14.
30 December 2025
Why Newmont stock is up today: gold rebounds and Fed minutes loom

Why Newmont stock is up today: gold rebounds and Fed minutes loom

Newmont shares rose 2.7% to $102.48 by midday Tuesday, rebounding after Monday’s nearly 6% drop. The move followed a Raymond James price target hike and steadier gold prices, with spot gold up 0.9% after its sharpest fall since October. Trading volume reached about 3.36 million shares. Investors awaited the Federal Reserve’s December minutes for signals on 2026 interest rates.
Pan American Silver stock today: PAAS climbs as silver rebounds after margin shakeout

Pan American Silver stock today: PAAS climbs as silver rebounds after margin shakeout

Pan American Silver shares rose 2.1% to $53.36 by midday Tuesday, following a 4.7% rebound in spot silver after Monday’s steep drop. About 2.6 million shares traded between $52.44 and $54.32. CME Group raised futures margin requirements after the close on Dec. 29, which helped trigger the earlier selloff. Investors await Fed minutes later Tuesday and Pan American’s Feb. 18 results.
30 December 2025
Orla Mining (ORLA) stock edges higher as gold rebounds; Fed minutes in focus

Orla Mining (ORLA) stock edges higher as gold rebounds; Fed minutes in focus

Orla Mining shares rose 0.7% to $13.80 in midday New York trading Tuesday, tracking a rebound in gold prices after Monday’s sharp selloff. Spot gold climbed 0.9% to $4,369.59 an ounce. Orla’s first quarterly dividend of $0.015 per share is set for Feb. 10, with a Jan. 12 record date. The company expects to start building its South Railroad project in Nevada by mid-2026.
30 December 2025
1 337 338 339 340 341 584

Stock Market Today

  • Oil Prices Surge and Stocks End Week Mixed After Trump's Iran Address
    April 3, 2026, 7:32 AM EDT. Oil prices surged over 11% after President Trump's national address signaled continued U.S. attacks on Iran without a clear end timeline, pushing U.S. crude above $111 per barrel. This spike, amid restricted shipping in the Strait of Hormuz where a fifth of global oil transits, caused early stock market losses. Despite this, the S&P 500 managed a modest 0.1% gain to 6,582.69, marking its first weekly rise since the Iran conflict began, up 3.4% for the week. The Dow Jones Industrial Average fell 61 points, or 0.1%, to 46,504.67, while the Nasdaq rose 0.2% to 21,879.18. Markets will close Friday for Good Friday. Elevated crude prices remain a key driver of volatile global stock movements.
Go toTop